ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2007 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 25, 2007--ImmunoGen, Inc. (Nasdaq: IMGN) will host a conference call at 4:30 p.m. ET on Thursday, February 1, 2007 to discuss the Company's financial results for the three-month period ended December 31, 2006 -- the second quarter of ImmunoGen's 2007 fiscal year. Management also will provide an update on the Company.
To access the live call by phone, dial 913-981-4900. No passcode is required. The call also may be heard through the Investor Relations section on the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through February 8, 2007.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Five anticancer compounds are in clinical testing through ImmunoGen and the Company's collaborators -- huN901-DM1 and huC242-DM4, which are wholly owned by ImmunoGen, AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-MCC-DM1, in development by Genentech. Amgen (formerly Abgenix), Biogen Idec, Biotest AG, Boehringer Ingelheim, Centocor (Johnson & Johnson), Genentech, Millennium Pharmaceuticals, Inc., and sanofi-aventis have licensed the right to develop and/or test TAP compounds to specific targets; ImmunoGen also has a broader collaboration with sanofi-aventis.
CONTACT:
ImmunoGen, Inc.
Executive Director
Investor Relations and Corporate Communications
Carol Hausner
617-995-2500
info@immunogen.com
SOURCE:
ImmunoGen, Inc.
